Allan James Darling
Geen lopende functies
Profiel
Allan James Darling worked as a Vice President at MedImmune LLC, Senior Vice President-Biologics Testing at BioReliance Corp., and Vice President-Technical Operations at Vtesse, Inc. He received an undergraduate degree from The University of Edinburgh and a doctorate from the University Of Dundee.
Eerdere bekende functies van Allan James Darling
| Bedrijven | Functie | Einde |
|---|---|---|
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
Vtesse, Inc.
 Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
BioReliance Corp.
 BioReliance Corp. Pharmaceuticals: MajorHealth Technology BioReliance Corp. provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies. It provides outsourced services to customers from most healthcare disciplines, including pharmaceutical, biopharmaceutical and chemical companies in the world. The firm also provides safety testing services focused on the rapidly growing biologics sector of the pharmaceutical and biotechnology industries. The company enables emerging and clinical stage companies who may lack the staff, expertise and financial resources to conduct many aspects of product development in-house. BioReliance was founded by Charles E. Bender in 1947 and is headquartered in Rockville, MD. | Corporate Officer/Principal | - |
Opleiding van Allan James Darling
| The University of Edinburgh | Undergraduate Degree |
| University Of Dundee | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 3 |
|---|---|
BioReliance Corp.
BioReliance Corp. Pharmaceuticals: MajorHealth Technology BioReliance Corp. provides testing and manufacturing services to pharmaceutical and biopharmaceutical companies. It provides outsourced services to customers from most healthcare disciplines, including pharmaceutical, biopharmaceutical and chemical companies in the world. The firm also provides safety testing services focused on the rapidly growing biologics sector of the pharmaceutical and biotechnology industries. The company enables emerging and clinical stage companies who may lack the staff, expertise and financial resources to conduct many aspects of product development in-house. BioReliance was founded by Charles E. Bender in 1947 and is headquartered in Rockville, MD. | Health Technology |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Vtesse, Inc.
Vtesse, Inc. BiotechnologyHealth Technology Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD. | Health Technology |